In this line, Osimertinib has recently been approved for use as adjuvant therapy after complete tumor resection in patients with stage IB-IIIA NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations [14]. This evidence concerns the gene EGFR and neoplasm.